Searchable abstracts of presentations at key conferences in endocrinology

ea0041ep701 | Growth hormone IGF axis - basic | ECE2016

Batch-to-batch consistency of a highly o-glycosylated long-acting human growth hormone (MOD-4023)

Moschcovich Laura , Guy Rachel , Felikman Yana , Zakar Miri , Hershkovitz Oren

Background: OPKO Biologics is a clinical-stage public company developing long-acting therapeutic proteins utilizing CTP technology. The technology involves fusion of the C-terminal peptide of human chorionic gonadotropin (hCG), which is highly O-glycosylated, to the target protein. CTP enabled the production of a long-acting human growth hormone (hGH) (MOD-4023), which supports a single weekly injection in growth hormone-deficient patients. MOD-4023 is manufactured as a non-vi...

ea0022p504 | Growth factors | ECE2010

Designing a long acting human GH by fusing the carboxyl-terminal peptide of human chorionic gonadotropin β subunit to the coding sequence of human GH

Fares Fuad , Guy Rachel , Bar-Ilan Ahuva , Felikman Yana , Fima Eyal

Human GH is a member of a family of closely related hormones that include prolactin and placental lactogen. GH regulates a wide variety of physiological processes, including growth and differentiation of muscle, bone and cartilage cells. The use of GH for the treatment of children with impaired linear growth has been accepted as an important therapeutic modality for many years. In addition, beneficial effects of GH replacement therapy in hypopituitary adults are well establish...